Overview Dividends

(INCY) Incyte - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45337C1027

JAKAFI, MONJUVI, PEMAZYRE, ICLUSIG, ZYNYZ

EPS (Earnings per Share)

EPS Growth (3y CAGR): 60.05%
EPS Trend (3y Corr): 26.7%

Last SUE: 4.00σ
Qual. Beats: 1

Revenue

Revenue Growth (3y CAGR): 15.15%
Revenue Trend (3y Corr): 87.0%

Last SUE: 2.47σ
Qual. Beats: 5

Risk via 10d forecast
Volatility	30.7%
Value at Risk 5%th	47.0%
Relative Tail Risk	-7.02%

Reward TTM
Sharpe Ratio	0.96
Alpha	24.66

Character TTM
Hurst Exponent	0.405
Beta	0.570
Beta Downside	0.638

Drawdowns 3y
Max DD	40.50%
Mean DD	21.22%
Median DD	24.09%

Description: INCY Incyte October 31, 2025

Incyte Corporation (NASDAQ: INCY) is a U.S.–based biopharmaceutical firm that discovers, develops, and commercializes specialty therapeutics across the United States, Europe, Canada, and Japan. Its approved portfolio includes ruxolitinib (JAKAFI/OPZELURA) for myelofibrosis, polycythemia vera and graft-versus-host disease; tafasitamab (MONJUVI/MINJUVI) for relapsed/refractory diffuse large B-cell lymphoma; pemigatinib (PEMAZYRE) for biliary tract cancers; ponatinib (ICLUSIG) for chronic myeloid leukemia and Ph-positive ALL; retifanlimab (ZYNYZ) for Merkel cell carcinoma; and axatilimab (NIKTIMVO) for chronic GVHD, plus a topical ruxolitinib cream for atopic dermatitis. The pipeline spans multiple modalities, including a CDK2 inhibitor for ovarian cancer, a KRAS G12D-targeted agent, and several immunomodulators for dermatologic and neuro-immune disorders.

Key quantitative points (FY 2023, per the company’s 10-K) show total revenue of approximately $2.5 billion, driven largely by JAKAFI and ICLUSIG, with a year-over-year growth rate of ~12 %. R&D expenditure was $720 million, representing roughly 29 % of revenue, underscoring a heavy reinvestment model typical for biotech firms. The JAK-inhibitor market is projected to expand at a CAGR of ~10 % through 2029, providing a favorable macro-trend for Incyte’s core assets, while the broader oncology biotech sector has seen a 15 % increase in M&A activity in 2024, indicating potential partnership or acquisition upside.

For a deeper quantitative assessment of Incyte’s valuation metrics and peer comparison, the ValueRay platform offers a data-driven dashboard worth exploring.

INCY Stock Overview

Market Cap in USD	20,806m
Sub-Industry	Biotechnology
IPO / Inception	1993-11-04
Return 12m vs S&P 500	18.8%
Analyst Rating	3.67 of 5

INCY Dividends

Currently no dividends paid

INCY Growth Ratios

Metric	Value
CAGR 3y	10.00%
CAGR/Max DD Calmar Ratio	0.25
CAGR/Mean DD Pain Ratio	0.47
Current Volume	2831.4k
Average Volume	2392.4k

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (1.19b TTM) > 0 and > 6% of Revenue (6% = 288.8m TTM)

FCFTA 0.19 (>2.0%) and ΔFCFTA 18.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 61.02% (prev 32.07%; Δ 28.95pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.20 (>3.0%) and CFO 1.25b > Net Income 1.19b (YES >=105%, WARN >=100%)

Net Debt (-2.41b) to EBITDA (1.63b) ratio: -1.48 <= 3.0 (WARN <= 3.5)

Current Ratio 3.19 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (201.4m) change vs 12m ago 2.85% (target <= -2.0% for YES)

Gross Margin 91.91% (prev 91.21%; Δ 0.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 84.87% (prev 81.31%; Δ 3.55pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 919.9 (EBITDA TTM 1.63b / Interest Expense TTM 1.67m) >= 6 (WARN >= 3)

Altman Z'' 4.78

(A) 0.46 = (Total Current Assets 4.28b - Total Current Liabilities 1.34b) / Total Assets 6.33b

(B) -0.01 = Retained Earnings (Balance) -85.5m / Total Assets 6.33b

(D) -0.04 = Book Value of Equity -70.8m / Total Liabilities 1.68b

Total Rating: 4.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 89.90

1. Piotroski 7.50pt = 2.50

2. FCF Yield 6.68% = 3.34

3. FCF Margin 24.87% = 6.22

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda -1.48 = 2.50

6. ROIC - WACC (= 27.87)% = 12.50

7. RoE 29.83% = 2.49

8. Rev. Trend 86.99% = 6.52

9. EPS Trend 26.70% = 1.33

What is the price of INCY shares?

As of November 20, 2025, the stock is trading at USD 103.89 with a total of 2,831,374 shares traded.
Over the past week, the price has changed by -3.95%, over one month by +20.56%, over three months by +22.34% and over the past year by +34.97%.

Is INCY a buy, sell or hold?

Incyte has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold INCY.

Strong Buy: 8
Buy: 3
Hold: 15
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the INCY price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	92.6	-10.9%
Analysts Target Price	92.6	-10.9%
ValueRay Target Price	113.8	9.5%

INCY Fundamental Data Overview November 11, 2025

Market Cap USD = 20.81b (20.81b USD * 1.0 USD.USD)
P/E Trailing = 17.9627
P/E Forward = 12.5
P/S = 4.3228
P/B = 4.0395
P/EG = 0.1286
Beta = 0.826
Revenue TTM = 4.81b USD
EBIT TTM = 1.54b USD
EBITDA TTM = 1.63b USD
Long Term Debt = 33.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 10.4m USD (from shortTermDebt, last quarter)
Debt = 41.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.41b USD (from netDebt column, last quarter)
Enterprise Value = 17.92b USD (20.81b + Debt 41.3m - CCE 2.93b)
Interest Coverage Ratio = 919.9 (Ebit TTM 1.54b / Interest Expense TTM 1.67m)
FCF Yield = 6.68% (FCF TTM 1.20b / Enterprise Value 17.92b)
FCF Margin = 24.87% (FCF TTM 1.20b / Revenue TTM 4.81b)
Net Margin = 24.69% (Net Income TTM 1.19b / Revenue TTM 4.81b)
Gross Margin = 91.91% ((Revenue TTM 4.81b - Cost of Revenue TTM 389.4m) / Revenue TTM)
Gross Margin QoQ = 92.75% (prev 92.13%)
Tobins Q-Ratio = 2.83 (Enterprise Value 17.92b / Total Assets 6.33b)
Interest Expense / Debt = 1.44% (Interest Expense 594.0k / Debt 41.3m)
Taxrate = 12.05% (58.1m / 482.3m)
NOPAT = 1.35b (EBIT 1.54b * (1 - 12.05%))
Current Ratio = 3.19 (Total Current Assets 4.28b / Total Current Liabilities 1.34b)
Debt / Equity = 0.01 (Debt 41.3m / totalStockholderEquity, last quarter 4.65b)
Debt / EBITDA = -1.48 (Net Debt -2.41b / EBITDA 1.63b)
Debt / FCF = -2.02 (Net Debt -2.41b / FCF TTM 1.20b)
Total Stockholder Equity = 3.98b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.78% (Net Income 1.19b / Total Assets 6.33b)
RoE = 29.83% (Net Income TTM 1.19b / Total Stockholder Equity 3.98b)
RoCE = 38.30% (EBIT 1.54b / Capital Employed (Equity 3.98b + L.T.Debt 33.5m))
RoIC = 35.98% (NOPAT 1.35b / Invested Capital 3.76b)
WACC = 8.11% (E(20.81b)/V(20.85b) * Re(8.12%) + D(41.3m)/V(20.85b) * Rd(1.44%) * (1-Tc(0.12)))
Discount Rate = 8.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.62%
[DCF Debug] Terminal Value 71.90% ; FCFE base≈724.9m ; Y1≈515.4m ; Y5≈276.3m
Fair Price DCF = 26.65 (DCF Value 5.23b / Shares Outstanding 196.3m; 5y FCF grow -33.99% → 3.0% )
EPS Correlation: 26.70 | EPS CAGR: 60.05% | SUE: 4.0 | # QB: 1
Revenue Correlation: 86.99 | Revenue CAGR: 15.15% | SUE: 2.47 | # QB: 5

Additional Sources for INCY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle